Európska únia - slovenčina - EMA (European Medicines Agency)

bayer ag - riociguat - hypertenzia, pľúca - antihypertenzíva pre pľúcnu arteriálnu hypertenziu - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnosť bola preukázaná v pau obyvateľstva vrátane aetiologies z idiopatická alebo dedičné pau alebo pah spojené s spojivového tkaniva ochorenia. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.